Carcinoma: all 6,718 studies

Page 16 of 68. Open to participants first (1,141), then studies with results posted, then the rest; newest registration first within each.

• Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT02923739Phase 2Results posted
• Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell CarcinomaTerminatedNCT02923531Phase 1/2Results posted
• Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical CancerCompletedNCT02921269Phase 2Results posted
• TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)CompletedNCT02920476Phase 2Results posted
• ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive TreatmentTerminatedNCT02917629Phase 2Results posted
• A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced DiseaseCompletedNCT02915783Phase 2Results posted
• Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In SituCompletedNCT02908178Results posted
• Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02901899Phase 2Results posted
• Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the BladderTerminatedNCT02901548Phase 2Results posted
• Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast CancerCompletedNCT02898207Phase 1Results posted
• Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by SurgeryCompletedNCT02896907Early Phase 1Results posted
• Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast CancerTerminatedNCT02892734Phase 2Results posted
• Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial CarcinomaTerminatedNCT02887248Phase 2Results posted
• Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast CancerTerminatedNCT02876640Phase 1Results posted
• Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal CancerCompletedNCT02873195Phase 2Results posted
• A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT02859324Phase 1/2Results posted
• Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)CompletedNCT02853344Phase 2Results posted
• Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02853318Phase 2Results posted
• Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)CompletedNCT02853305Phase 3Results posted
• Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder CancerCompletedNCT02844816Phase 2Results posted
• Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)CompletedNCT02844075Phase 2Results posted
• Trial of Pembrolizumab for Advanced Penile Squamous Cell CarcinomaTerminatedNCT02837042Phase 2Results posted
• Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver CancerCompletedNCT02837029Phase 1Results posted
• Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular CarcinomaCompletedNCT02834780Phase 1Results posted
• A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid TumorsTerminatedNCT02834247Phase 1Results posted
• Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal MelanomaTerminatedNCT02831933Phase 2Results posted
• Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction CancerCompletedNCT02830594Phase 2Results posted
• A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical StudiesCompletedNCT02829775Phase 2/3Results posted
• A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver CancerTerminatedNCT02828124Phase 1/2Results posted
• Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell CarcinomasCompletedNCT02828111Phase 2Results posted
• Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx CancerTerminatedNCT02827838Early Phase 1Results posted
• A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)CompletedNCT02821754Phase 2Results posted
• A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid TumorsCompletedNCT02819843Phase 2Results posted
• Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder CancerCompletedNCT02808143Phase 1Results posted
• Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced MalignanciesCompletedNCT02807844Phase 1/2Results posted
• Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial CarcinomaCompletedNCT02807636Phase 3Results posted
• Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney CancerTerminatedNCT02795819Phase 1Results posted
• Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCCCompletedNCT02795429Phase 1/2Results posted
• Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic AlterationsCompletedNCT02795156Phase 2Results posted
• The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC StudyCompletedNCT02793128Phase 3Results posted
• Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line TreatmentCompletedNCT02789137Results posted
• Genomic Based Assignment of Therapy in Advanced Urothelial CarcinomaCompletedNCT02788201Phase 2Results posted
• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT02785939Phase 2/3Results posted
• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesCompletedNCT02785913Phase 2Results posted
• Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell CarcinomaTerminatedNCT02782715Phase 1/2Results posted
• Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell CarcinomaTerminatedNCT02781506Phase 2Results posted
• Clinical Outcome Of Advanced Renal Cell Carcinoma In TaiwanCompletedNCT02776644Results posted
• Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain MetastasisTerminatedNCT02774681Phase 2Results posted
• Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT02771626Phase 1/2Results posted
• Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersCompletedNCT02766335Phase 2/3Results posted
• Contrast-enhanced Ultrasound Evaluation of ChemoembolizationCompletedNCT02764801Phase 3Results posted
• Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung CancerTerminatedNCT02762877Results posted
• Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial ChemoembolizationTerminatedNCT02762266Phase 3Results posted
• Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome PatientsCompletedNCT02762084Phase 2Results posted
• Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedCompletedNCT02761057Phase 2Results posted
• Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell CarcinomaCompletedNCT02760498Phase 2Results posted
• Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian CancerCompletedNCT02759588Phase 1/2Results posted
• Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus NormothermiaCompletedNCT02739698Phase 2Results posted
• ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsCompletedNCT02737501Phase 3Results posted
• Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell CarcinomaCompletedNCT02729194Early Phase 1Results posted
• S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)CompletedNCT02728596Not applicableResults posted
• Copanlisib in Treating Patients With Persistent or Recurrent Endometrial CancerCompletedNCT02728258Phase 2Results posted
• MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell CarcinomaCompletedNCT02724020Phase 2Results posted
• Nivolumab in Treating Patients With Metastatic Adrenocortical CancerTerminatedNCT02720484Phase 2Results posted
• Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck CancerCompletedNCT02718820Phase 1/2Results posted
• Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the LungTerminatedNCT02713828Phase 1/2Results posted
• Genetic Predictors of Benefit to PembrolizumabTerminatedNCT02710396Phase 2Results posted
• Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid TumorsTerminatedNCT02709889Phase 1/2Results posted
• BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck CancerTerminatedNCT02706691Phase 2Results posted
• Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ MalignanciesTerminatedNCT02706392Phase 1Results posted
• Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid TumorsCompletedNCT02705105Phase 1/2Results posted
• TAE and MWA Combination Therapy in Early-stage Hepatocellular CarcinomaTerminatedNCT02704130Not applicableResults posted
• Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)CompletedNCT02702414Phase 2Results posted
• Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)CompletedNCT02702401Phase 3Results posted
• [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver CancerCompletedNCT02695628Phase 2Results posted
• Microparticle Enhanced Cytotoxic Transarterial Embolization TherapyCompletedNCT02694562Not applicableResults posted
• Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial CancerTerminatedNCT02693717Phase 2Results posted
• Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin CancerCompletedNCT02690948Phase 1/2Results posted
• Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell CarcinomaCompletedNCT02687139Not applicableResults posted
• Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT02684253Phase 2Results posted
• Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCCCompletedNCT02670122Results posted
• Trial of X4P-001 in Participants With Advanced Renal Cell CarcinomaCompletedNCT02667886Phase 1/2Results posted
• Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)CompletedNCT02662608Not applicableResults posted
• Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell CarcinomaCompletedNCT02662244Not applicableResults posted
• Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by SurgeryTerminatedNCT02658812Phase 2Results posted
• Pembrolizumab (Keytruda) in Advanced Hepatocellular CarcinomaCompletedNCT02658019Phase 2Results posted
• Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial CancerCompletedNCT02657928Phase 2Results posted
• A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)TerminatedNCT02657369Phase 2Results posted
• Intraoperative Folate Targeted Fluorescence in Renal Cell CarcinomaCompletedNCT02645409Not applicableResults posted
• A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersCompletedNCT02643303Phase 1/2Results posted
• A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell CarcinomaCompletedNCT02639182Phase 2Results posted
• Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )TerminatedNCT02633800Phase 2Results posted
• Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced CholangiocarcinomaCompletedNCT02631590Phase 2Results posted
• MK-3475 Immunotherapy in Endometrial CarcinomaCompletedNCT02630823Phase 1Results posted
• A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)CompletedNCT02627963Phase 3Results posted
• Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)CompletedNCT02626000Phase 1Results posted
• Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell CarcinomaCompletedNCT02619253Phase 1Results posted
• IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral CavityCompletedNCT02609386Phase 2Results posted
• Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaCompletedNCT02605967Phase 2Results posted
• Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary TumorsCompletedNCT02599324Phase 1/2Results posted

← Carcinoma overview